CERVARIX
[Human Papillomavirus Bivalent (Types 16 and 18) Vaccine, Recombinant] Suspension
for Intramuscular Injection
CERVARIX [Human Papillomavirus Bivalent (Types 16 and 18) Vaccine, Recombinant] is a non-infectious recombinant, AS04-adjuvanted vaccine that contains recombinant L1 protein, the major antigenic protein of the capsid, of oncogenic HPV types 16 and 18. The L1 proteins are produced in separate bioreactors using the recombinant Baculovirus expression vector system in a serum-free culture media composed of chemically-defined lipids, vitamins, amino acids, and mineral salts. Following replication of the L1 encoding recombinant Baculovirus in Trichoplusia ni insect cells, the L1 protein accumulates in the cytoplasm of the cells. The L1 proteins are released by cell disruption and purified by a series of chromatographic and filtration methods. Assembly of the L1 proteins into virus-like particles (VLPs) occurs at the end of the purification process. The purified, non-infectious VLPs are then adsorbed on to aluminum (as hydroxide salt). The adjuvant system, AS04, is composed of 3-O-desacyl-4'-monophosphoryl lipid A (MPL) adsorbed on to aluminum (as hydroxide salt).
CERVARIX (human papillomavirus bivalent vaccine) is prepared by combining the adsorbed VLPs of each HPV type together with the AS04 adjuvant system in sodium chloride, sodium dihydrogen phosphate dihydrate, and Water for Injection.
CERVARIX (human papillomavirus bivalent vaccine) is a sterile suspension for intramuscular injection. Each 0.5-mL dose is formulated to contain 20 mcg of HPV type 16 L1 protein, 20 mcg of HPV type 18 L1 protein, 50 mcg of the 3-O-desacyl-4'-monophosphoryl lipid A (MPL), and 0.5 mg of aluminum hydroxide. Each dose also contains 4.4 mg of sodium chloride and 0.624 mg of sodium dihydrogen phosphate dihydrate. Each dose may also contain residual amounts of insect cell and viral protein ( < 40 ng) and bacterial cell protein ( < 150 ng) from the manufacturing process. CERVARIX (human papillomavirus bivalent vaccine) does not contain a preservative.
Before receiving this medication, tell your doctor or pharmacist if you are allergic to it; or to latex; or to other vaccines; or if you have any other allergies. This product may contain inactive ingredients, which can cause allergic reactions or other problems. Talk to your pharmacist for more details.
Before receiving this vaccination, tell your doctor or pharmacist your medical history, especially of: immune system problems (such as HIV infection), bleeding disorders (such as hemophilia, thrombocytopenia), current fever/illness.
This vaccine can cause some patients to faint, which could cause falling and injury. To reduce the risk of this side effect, your doctor may recommend that you stay in a sitting or lying position for 15 minutes after the injection....
Last reviewed on RxList: 10/30/2009
This monograph has been modified to include the generic and brand name in many instances.
Report Problems to the Food and Drug Administration
You are encouraged to report negative side effects of prescription drugs to the FDA. Visit the FDA MedWatch website or call 1-800-FDA-1088.
Find out what women really need.
RxList does not provide medical advice, diagnosis or treatment. See additional information.
Updated & New